Configurational requirements of the sugar moiety for the pharmacological activity of anthracycline disaccharides

Biochemical Pharmacology

Volumn 57, Issue 10, 1999, Pages 1133-1139

  Arcamone, Federico ^a   Animati, Fabio ^a   Bigioni, Mario ^a   Capranico, Giovanni ^b   Caserini, Claudia ^b   Cipollone, Amalia ^a   De Cesare, Michelandrea ^b   Ettorre, Alessandro ^a   Guano, Fulvio ^b   Manzini, Stefano ^a   Monteagudo, Edith ^a   Pratesi, Graziella ^b   Salvatore, Carmela ^a   Supino, Rosanna ^b   Zunino, Franco ^b  

^a Menarini Ricerche SpA   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Anthracyclines; Chemistry; Structure activity; Topoisomerase

Indexed keywords

AMINOSUGAR; ANTHRACYCLINE DERIVATIVE; DAUNORUBICIN; DAUNORUBICIN DERIVATIVE; DAUNOSAMINE; DISACCHARIDE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; IDARUBICIN; IDARUBICIN DERIVATIVE; MEN 10732; MEN 10733; MEN 10746; MEN 10749; RECOMBINANT ENZYME; SUGAR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GRAFT; CARBOHYDRATE ANALYSIS; CONTROLLED STUDY; CYTOTOXICITY; DNA CLEAVAGE; DRUG CONFORMATION; DRUG DESIGN; DRUG DNA BINDING; FEMALE; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; DISACCHARIDES; DISEASE MODELS, ANIMAL; DNA; HUMANS; IDARUBICIN; INHIBITORY CONCENTRATION 50; MAGNETIC RESONANCE SPECTROSCOPY; MICE; MICE, NUDE; MOLECULAR CONFORMATION; RECOMBINANT PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0033562909     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(99)00025-8     Document Type: Article

References (17)

1. Weiss R.B. The anthracyclines Will we ever find a better doxorubicin? Semin Oncol. 19:1992;670-686.
2. Arcamone F, Doxorubicin. Anticancer Antibiotics, Medicinal Chemical Series, Vol. 17. Academic Press, New York, 1981.
3. Zunino F., Capranico G. DNA topoisomerase II as the primary target of anti-tumor anthracyclines. Anticancer Drug Des. 5:1992;307-317.
4. Zunino F., Capranico G. Sequence-selective groove binders. Teicher B., Cancer Therapeutics Experimental and Clinical Agents . 1997;195-214 Humana Press Inc, Totowa, NJ.
5. Capranico G., Supino R., Binaschi M., Capolongo L., Grandi M., Suarato A., Zunino F. Influence of structural modifications at the 3′ and 4′ positions of doxorubicin on the drug ability to trap topoisomerase II and to overcome multidrug resistance. Mol Pharmacol. 45:1994;908-915.
6. Animati F., Berettoni M., Cipollone A., Franciotti M., Lombardi P., Monteagudo E., Arcamone F. New anthracycline disaccharides synthesis of L-daunosaminyl-α(1 →4)-2-deoxy-L-rhamnosyl and of L-daunosaminyl-α-(1 → 4)-2-deoxy-L-fucosyl daunorubicin analogues. J Chem Soc Perkin Trans I. 1996;1327-1329.
7. McGhee J.D., Von Hippel P.H. Theoretical aspects of DNA-protein interactions Co-operative and non-co-operative binding of large ligands to a one-dimensional homogeneous lattice . J Mol Biol. 86:1974;469-489.
8. Chaires J.B., Dattagupta N., Crothers D.M. Self-association of daunomycin. Biochemistry. 21:1982;3927-3932.
9. Wasserman R.A., Austin C.A., Fisher L.M., Wang J.C. Use of yeast in the study of anticancer drugs targeting DNA topoisomerases Expression of a functional recombinant human DNA topoisomerase IIa in yeast . Cancer Res. 53:1993;3591-3596.
10. Worland S.T., Wang J.C. Inducible overexpression, purification, and active site mapping of DNA topoisomerase II from the yeast Saccharomyces cerevisiae. J Biol Chem. 264:1989;4412-4416.
11. Animati F., Arcamone F., Bigioni M., Capranico G., Caserini C., De Cesare M., Lombardi P., Pratesi G., Salvatore C., Supino R., Zunino F. Biochemical and pharmacological activity of novel 8-fluoroanthracyclines Influence of stereochemistry and conformation . Mol Pharmacol. 50:1996;603-609.
12. Binaschi M., Supino R., Gambetta R.A., Giaccone G., Prosperi E., Capranico G., Cataldo I., Zunino F. MRP gene everexpression in a human doxorubicin-resistant SCLC cell line Alterations in cellular pharmacokinetics and in pattern of cross-resistance . Int J Cancer. 62:1995;84-89.
13. Supino R, MTT assay. In: Methods in Molecular Biology: In Vitro Toxicity Testing Protocols (Eds. O'Hare S and Atterwill CK), pp. 137-149. Humana Press Inc., Totowa, NJ, 1995.
14. Zunino F., Gambetta R.A., Di Marco A., Velcich A., Zaccara A., Quadrifoglio F., Crescenzi V. The interaction of adriamycin and its beta anomer with DNA. Biochim Biophys Acta. 476:1977;38-46.
15. nACG) covalent adduct . Proc Natl Acad Sci USA. 88:1991;4845-4849.
16. Supino R., Necco A., Dasdia T., Casazza A.M., Di Marco A. Relationship between effects on nucleic acid synthesis in cell cultures and cytotoxicity of 4-demethoxy derivatives of daunorubicin and adriamicin. Cancer Res. 37:1997;4523-4528.
17. Arcamone F., Animati F., Berettoni M., Bigioni M., Capranico G., Casazza A.M., Caserini C., Cipollone A., De Cesare M., Franciotti M., Lombardi P., Madami A., Manzini S., Monteagudo E., Polizzi D., Pratesi G., Righetti S.C., Salvatore C., Supino R., Zunino F. Doxorubicin disaccharide analogue Apoptosis-related improvement of efficacy in vivo . J Natl Cancer Inst. 89:1997;1217-1223.